SCHEMBL2432565

SCHEMBL2432565

CCN(c1cc(-c2ccc(NC(=O)c3cscn3)cc2)sc1C(=O)OC)C(=O)[C@H]1CC[C@H](C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
GRM4 Q14833 1/20 0.40
KDM4E B2RXH2 2/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.37
TP53 P04637 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MAP3K5 Q99683 1/20 0.35
PTPN1 P18031 2/20 0.35
NPC1 O15118 1/20 0.34
CASP3 P42574 1/20 0.34
RAB9A P51151 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
EZH2 Q15910 1/20 0.33
ROCK2 O75116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432576 1.00 MAPT (0.40) MAPTGRM4KDM4EHTTATM
SCHEMBL2435984 0.92 ALDH1A1 (0.39) MAPTGRM4KDM4EHTTATM
SCHEMBL2435978 0.92 ALDH1A1 (0.39) MAPTGRM4KDM4EHTTATM
SCHEMBL2428710 0.92 GRM4 (0.37) GRM4MAP3K5EZH2ROCK2
SCHEMBL2428709 0.92 GRM4 (0.37) GRM4MAP3K5EZH2ROCK2
SCHEMBL2433539 0.91 GRM4 (0.38) MAPTGRM4KDM4EHTTATM
SCHEMBL2429257 0.91 GRM4 (0.38) MAPTGRM4KDM4EHTTATM
SCHEMBL2429254 0.91 GRM4 (0.38) MAPTGRM4KDM4EHTTATM
SCHEMBL2433533 0.91 GRM4 (0.38) MAPTGRM4KDM4EHTTATM
SCHEMBL2431283 0.88 GRM4 (0.38) MAPTGRM4KDM4EHTTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086966-B1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-09-14 EP disclosed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS EIF2AK2, HAVCR2, GTF3C2 MAPT 3802/4885GRM4 3141/4885KDM4E 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.